catalyst · primary record
Allopurinol + Dotinurad
Phase readout · 2027-12-31 · Tophaceous Gout
| Company | Crystalys Therapeutics |
|---|---|
| Ticker | Not stated |
| Impact | high |
| Detail | P3 primary completion · NCT07089888 |
| Source | ClinicalTrials.gov |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:50.932Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: Crystalys Therapeutics:Allopurinol + Dotinurad:2027-12-31:P3 primary completion · NCT07089888
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.